BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6970035)

  • 1. An assay of deoxyadenosine and adenosine in human plasma by HPLC.
    Koller CA; Stetson PL; Nichamin LD; Mitchell BS
    Biochem Med; 1980 Oct; 24(2):179-84. PubMed ID: 6970035
    [No Abstract]   [Full Text] [Related]  

  • 2. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
    Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
    Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP depletion as a consequence of adenosine deaminase inhibition in man.
    Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of deoxycoformycin.
    Major PP; Agarwal RP; Kufe DW
    Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of adenosine deaminase inhibitors on the apparent rate of phosphorylation of deoxyadenosine.
    Deibel MR; Coleman MS; Hutton JJ
    Biochem Med; 1981 Jun; 25(3):288-97. PubMed ID: 6973972
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of 3H-thymidine incorporation by adenosine and deoxyadenosine in human peripheral lymphocytes and malignant lymphoid cell lines.
    van der Krann PM; van Zandvoort PM; De Abreu RA; Bakkeren JA; van Laarhoven JP; de Bruijn CH
    Adv Exp Med Biol; 1986; 195 Pt B():213-9. PubMed ID: 3490120
    [No Abstract]   [Full Text] [Related]  

  • 9. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
    Kefford RF; Fox RM
    Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal handling of 2'-deoxyadenosine and adenosine in humans and mice.
    Kuttesch JF; Nelson JA
    Cancer Chemother Pharmacol; 1982; 8(2):221-9. PubMed ID: 6980741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin.
    Major PP; Agarwal RP; Kufe DW
    Cancer Chemother Pharmacol; 1983; 10(2):125-8. PubMed ID: 6600984
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
    Bagnara AS; Hershfield MS
    Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleotide levels and metabolism of adenosine and deoxyadenosine in intact erythrocytes deficient in adenosine deaminase.
    Webster DR; Simmonds HA; Perrett D; Levinsky RJ
    Adv Exp Med Biol; 1984; 165 Pt A():363-6. PubMed ID: 6609529
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of glycolysis in deoxyadenosine induced ATP depletion and dATP accumulation in red cells.
    Koller CA; Orringer EP; Berkowitz LR; Mulhern AT
    Prog Clin Biol Res; 1984; 165():227-39. PubMed ID: 6334314
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of multiple myeloma with deoxycoformycin.
    Belch AR; Henderson JF; Brox LW
    Cancer Chemother Pharmacol; 1985; 14(1):49-52. PubMed ID: 3871175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
    Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; PĂ©rignon JL
    Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
    Kang GJ; Kimball AP
    Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of adenosine deaminase activity results in cytotoxicity to T lymphoblasts in vivo.
    Mitchell BS; Koller CA; Heyn R
    Blood; 1980 Sep; 56(3):556-9. PubMed ID: 6967747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients.
    Hirschhorn R; Roegner-Maniscalco V; Kuritsky L; Rosen FS
    J Clin Invest; 1981 Dec; 68(6):1387-93. PubMed ID: 7033281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.